This CME audio podcast explores strategies to manage EGFR inhibitor-associated dermatologic toxicities in patients with NSCLC. Experts review the pathophysiology of these side effects and emphasize their impact on quality of life and the importance of early intervention. Practical, guideline-adherent prophylaxis and management approaches are discussed that highlight interprofessional collaboration to optimize outcomes and help patients remain on lifesaving therapies. Finally, our experts offer insights on educating patients, minimizing treatment interruptions, and supporting multidisciplinary care.
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Enhance your NSCLC care with practical strategies to manage dermatologic toxicities associated with EGFR inhibitors and improve QoL and outcomes.

Transcript
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
closeTranscript
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
closeAnnouncer:
Welcome to CME on ReachMD. This activity, titled “Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities” is provided by Prova Education.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
Dr. Leventhal:
EGFR inhibitors are commonly used for treating non-small cell lung cancer. Do you have adequate knowledge to manage the dermatologic toxicities associated with this therapy?
This is CME on ReachMD, and I'm Dr. Jonathan Leventhal, director of the Onco-Dermatology Clinic at Yale Cancer Center.
Ms. Singh-Kandah:
And I'm Shanaz Singh-Kandah, an oncology nurse practitioner at Columbia University Medical Center.
Dr. Leventhal, can you provide an overview of the dermatologic toxicities that are associated with EGFR inhibitors and can occur in patients with non-small cell lung cancer?
Dr. Leventhal:
Absolutely. EGFR inhibitors are an important class of cancer medicine that's used to treat various cancers, especially non-small cell lung cancer. And these EGFR inhibitors block receptors on tumors that are also expressed on the skin, hair, and nails; that's why they result in dermatologic toxicities. And these cutaneous side effects are especially common. The ones that I think are most clinically relevant include the acneiform rash, and that presents with papules and pustules on the face, scalp, chest, and back. And it really could be widespread. In addition, patients can get paronychia infection of their nails, resulting in painful ingrown nails, and hypergranulation tissue, which we call pyogenic granulomas. Patients also can present with xerosis or dry skin as well as pruritus and hair changes, including hair thinning on the scalp and hirsutism of the face as well as eyelashes that can become elongated and curvy.
These toxicities can result in negative impact on quality of life. And in severe cases, the oncologist might even hold treatment or reduce the dose. That underscores why early intervention and treatment is really key to improve overall outcomes.
And the way we grade these rashes are based upon the CTCAE criteria, which basically is based upon body surface area of involvement for the rash and the severity or impact on quality of life. So for rashes that are mild or low grade, we treat the acneiform rash with topical steroids and topical antibiotics as well as oral antibiotics such as doxycycline. For rashes that are higher grade, we’ll use prednisone for a week or so and hold the cancer treatment. And for rashes that are really recalcitrant to therapy, we often use things like low-dose isotretinoin, which can be helpful in managing the acneiform rash.
And I think a key point is that there's a lot that we can do with patient education to help prevent the rash, including the use of these topical agents, sun protection, and oral antibiotics. And we know that this can improve patients’ quality of life and overall survival outcomes.
Ms. Singh-Kandah:
Thank you. That was a super helpful overview, Dr. Leventhal.
So as a dermatologist, when a patient is having a skin toxicity, especially earlier on from an EGFR inhibitor, when do you prefer to see them in clinic?
Dr. Leventhal:
That's a great question. Oncologists do a very good job at managing dermatologic toxicities in their cancer patients, especially kind of the lower-grade reactions. But when patients present with higher-grade toxicities, so those on the Common Terminology Criteria for Adverse Events, the CTCAE criteria, that are grade 2 or 3, really impacting quality of life, or those that don't respond to first-line therapy with topical agents and supportive therapy, I think those are the patients that really should see dermatologists promptly.
Ms. Singh-Kandah:
Okay, great, that makes sense.
Dr. Leventhal:
Shahnaz, can you review some of the guidelines for preventing dermatologic toxicities associated with EGFR inhibitors?
Ms. Singh-Kandah:
Sure. So with more EGFR inhibitor medications on the market, it's super important for us to be proactive rather than reactive. So a proactive lifestyle to help reduce the risk of dermatologic toxicity is very important. In a systematic review of 13 studies using amivantamab, there was a 46% reduction in the risk of all-grade skin rash, just by using prophylactic antibiotics with or without topical skin therapies, and a 39% reduction in the risk of paronychia. So we do know that prophylactic treatment is very important, so we usually tend to recommend, based upon EGFR therapy, an oral antibiotic in the beginning, such as doxycycline, and a topical cream such as hydrocortisone, along with a rich moisturizer and a sunscreen daily. I also advise my patients to limit sun exposure during treatment and for a couple of months following treatment. And as advanced practice providers and nurses, it's super helpful for us to familiarize ourselves with what derm toxicity looks like with EGFR inhibitors and how to treat early. When we're familiar with the pattern on how it arises, when it arises, it's easier to educate patients on the warning signs.
Dr. Leventhal:
That's great. Shahnaz, can you tell us more about the important role that nurses and advanced practice providers play with patient care and education?
Ms. Singh-Kandah:
Yeah, sure. So nurses and advanced practice providers are usually involved in the education and the management of toxicities of EGFR inhibitors. At my practice, we do a thorough baseline visit, which I'll share a little bit more about later in this session, to take the time to really educate patients on potential toxicities and when to call. Spending this time in the very beginning really does help a lot, especially when toxicity arises, and it's honestly an ongoing discussion at every visit.
We work closely with pharmacists if a dose reduction is needed or getting a compound medication for the management of more advanced derm toxicity. So our pharmacy colleagues really do become super helpful when needing dose reduction or a more advanced medication.
Dr. Leventhal:
Great.
For those just tuning in, you're listening to CME on ReachMD. I'm Dr. Jonathan Leventhal, and here with me today is Shahnaz Singh-Kandah. We're discussing the management of dermatologic toxicities associated with EGFR inhibitors in patients with non-small cell lung cancer.
Ms. Singh-Kandah:
So, Dr. Leventhal, can you describe interprofessional best practices for managing dermatologic toxicities associated with EGFR inhibitors?
Dr. Leventhal:
Yeah, I think a really important component is multidisciplinary collaborative care, integrating dermatologic assessment with the overall oncology care. And I think that can be challenging in various practice settings. So something that's really important to consider is that oncologists should seek dermatology allies who they can rely on to help coordinate urgent referrals and really close communication between recommendations of dermatologic care and oncologic treatment. And I think that tertiary care centers and large cancer hospitals, this happens more regularly. In the community, my advice is for oncologists to really seek partners and dermatologists who can really help provide multidisciplinary care.
And regarding the best practices for managing EGFR inhibitor dermatologic toxicities really depends on the grade and following the recommended guidelines. So for grade 1 and 2 rashes, topical steroids and doxycycline, as we discussed. For grade 3, adding prednisone for a week can really be helpful. And patients who present with severe superinfection and grade 4 often require hospitalization, IV antibiotics, and supportive care. And as I mentioned earlier, in patients who have recalcitrant acneiform rash, we often use low-dose isotretinoin, and that can be super helpful. For treating the paronychia, we’ll often use topical antibiotics and antiseptic soaks, like dilute vinegar soaks. We can also treat the pyogenic granulomas that are quite painful with local destructive modalities, this includes silver nitrate, timolol gel, and in really recalcitrant cases, nail avulsion by dermatologist, a surgeon, or podiatrist can be curative.
Ms. Singh-Kandah:
Thank you for that overview. And honestly, I can't overemphasize how important the collaboration is between medical oncology and dermatology, especially when it comes to managing these toxicities that, outside of medical oncology, it definitely becomes more difficult. So having a relationship with a dermatologist, having someone who can evaluate them early on is so helpful, especially when the rash is not mitigated by standard therapy, as you mentioned.
Dr. Leventhal:
Yeah. And I think something that you spoke about earlier is so important. Nurses and advanced practice providers often have the ability to spend a great deal of time with patients, checking in on patients, going over checklists of adverse events. And I think that they play such a crucial role in managing and educating patients who are undergoing treatment with an EGFR inhibitor.
Ms. Singh-Kandah:
Absolutely.
Dr. Leventhal:
Shahnaz, can you provide some real-world recommendations to promote guideline adherence and patient engagement?
Ms. Singh-Kandah:
Sure. So I found that creating a comprehensive checklist of items that you want to review with patients at the beginning of EGFR inhibitor therapy is so helpful. So I have a background in clinical research, and part of that is enrolling patients onto trials and doing a thorough pretreatment visit which includes explaining to them what the therapy is and toxicities to look out for. So in addition to getting their medical history, we are also looking to see if they've had a history of past skin disorders, or have they had skin reactions to other treatments? Patients that are on trials are monitored more closely because it is investigational therapy. So we find that we're able to treat toxicities earlier on because we're in regular communication with patients and they know when to call when a toxicity arises.
And I say that the same can be true for standard of care patients. Encouraging them to reach out when a derm toxicity arises, rather than waiting for their next scheduled visit, can potentially reduce the severity of toxicity and allow them to maximize their time on therapy.
In addition, EGFR inhibitor medications such as amivantamab may cause a scalp rash in some patients that is managed differently than skin rash. So educating patients on these particular side effects and being rigorous with prophylactic treatment is critical. Also letting patients know that if they've developed any sort of scalp rash or a rash outside of what they've already experienced or reported, to notify their teams immediately.
And we found that these thorough baseline visits, along with the taking the time to educate patients and showing them what a potential rash looks like, when it could arise, and what to look out for outside of your typical EGFR inhibitor rash, really does help minimize the severity of these rashes because we're introducing therapies and management of these toxicities earlier on.
Dr. Leventhal:
Such great points. Patient education, checklists, frequent communication. I would add that it is so critical to manage these side effects promptly and preemptively; it allows these cancer patients to remain on their lifesaving treatments. They can stay on their treatments longer. They have reduced chances of having to hold or reduce the dose of their treatments. And this is really crucial in achieving better clinical outcomes.
Ms. Singh-Kandah:
Definitely.
Dr. Leventhal:
Well, this has certainly been a fascinating conversation, but before we wrap up, Shahnaz, can you share your one take-home message with our audience?
Ms. Singh-Kandah:
Sure. I would say that our goal as providers is always for the patients to have a great quality of life while treating their cancer. Many of these patients we're treating are continuing to work and live their life per usual, so it's great to make that as easy and seamless as possible for them.
Nurses and advanced practice providers play a big role in helping patients have a great quality of life by encouraging the patient to reach out early when toxicity arises, the why behind using prophylactic treatment and being compliant with it, and also working closely with our colleagues, such as dermatology. Taking these measures can help us maximize patients’ time on therapy.
Dr. Leventhal:
Such great points. I would say, for me, I would echo that and also emphasize the importance of multidisciplinary care to not only improve quality of life, but really to improve overall clinical outcomes and survival as cancer patients with non-small cell lung cancer are able to remain on their EGFR inhibitor therapies.
And that's all the time we have today. So want to thank our audience for listening in and thank you, Shahnaz, for joining me and for sharing all of your valuable insights. It was great speaking with you today.
Ms. Singh-Kandah:
My pleasure. Thank you for having me.
Announcer:
You have been listening to CME on ReachMD. This activity is provided by Prova Education.
To receive your free CME credit, or to download this activity, go to ReachMD.com/CME. Thank you for listening.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Jonathan Leventhal, MD
Associate Professor of Dermatology
Yale University School of Medicine
New Haven, CTDr. Leventhal has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: OnQuality
Receives royalties: Elsevier
Consulting fees: La Roche Posay, Regeneron, SanofiShahnaz Singh-Kandah, NP
Oncology Nurse Practitioner
Columbia University Medical Center
New York, NYMs. Singh-Kandah has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Other: Conference travel for JanssenReviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Bing-E Xu, PhD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Review the pathophysiology of EGFRi-associated dermatologic toxicity and its relevance to prophylaxis and team-based management
- Incorporate guideline-adherent strategies for EGFRi-associated dermatologic toxicity prophylaxis and management protocols
- Implement practical recommendations that minimize EGFRi-associated dermatologic toxicity-associated therapy interruptions and maximize patients’ quality of life and survival
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, pulmonologists, dermatologists, and advanced practice professionals as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with NSCLC.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 contact hour(s)/0.025 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-007-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit(s). Approval is valid until 1/6/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Affairs, LLC
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Patient Partners in NSCLC: Managing Skin Toxicities Associated With EGFR Inhibitors
Show more
Overview
This CME audio podcast explores strategies to manage EGFR inhibitor-associated dermatologic toxicities in patients with NSCLC. Experts review the pathophysiology of these side effects and emphasize their impact on quality of life and the importance of early intervention. Practical, guideline-adherent prophylaxis and management approaches are discussed that highlight interprofessional collaboration to optimize outcomes and help patients remain on lifesaving therapies. Finally, our experts offer insights on educating patients, minimizing treatment interruptions, and supporting multidisciplinary care.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Jonathan Leventhal, MD
Associate Professor of Dermatology
Yale University School of Medicine
New Haven, CTDr. Leventhal has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: OnQuality
Receives royalties: Elsevier
Consulting fees: La Roche Posay, Regeneron, SanofiShahnaz Singh-Kandah, NP
Oncology Nurse Practitioner
Columbia University Medical Center
New York, NYMs. Singh-Kandah has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Other: Conference travel for JanssenReviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Bing-E Xu, PhD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Review the pathophysiology of EGFRi-associated dermatologic toxicity and its relevance to prophylaxis and team-based management
- Incorporate guideline-adherent strategies for EGFRi-associated dermatologic toxicity prophylaxis and management protocols
- Implement practical recommendations that minimize EGFRi-associated dermatologic toxicity-associated therapy interruptions and maximize patients’ quality of life and survival
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, pulmonologists, dermatologists, and advanced practice professionals as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with NSCLC.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 contact hour(s)/0.025 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-007-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit(s). Approval is valid until 1/6/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Affairs, LLC
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Patient Partners in NSCLC: Managing Skin Toxicities Associated With EGFR Inhibitors
Show more
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
Love Story: Lipid Education for Women’s Heart Health
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Personalizing Care Within the RCC Treatment Paradigm
Navigating Myasthenia Gravis in Adolescents and Young Adults
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?